|
Market Closed -
Nasdaq
21:00:00 04/09/2026 BST
|
5-day change | 1st Jan Change | ||
| 63.96 USD | +0.13% |
|
+5.11% | +65.53% |
| 09-05 | Royalty Pharma Announces Update on Novartis Phase 3 Topline Results for Pelacarsen | CI |
| 09-02 | Teva's immune disorder drug meets main goal in mid-stage trial | RE |
| Market Cap | 28.48B 24.51B 23.06B 21.06B 39.4B 2,689B 39.51B 272B 106B 1,380B 107B 105B 4,444B | P/E 2026 * |
25.9x | P/E 2027 * | 18.1x |
|---|---|---|---|---|---|
| Enterprise Value | 37.59B 32.35B 30.43B 27.8B 52.01B 3,549B 52.15B 360B 140B 1,821B 141B 138B 5,866B | EV / Sales 2026 * |
10.8x | EV / Sales 2027 * | 9.9x |
| Free-Float |
72.41% | Yield 2026 * |
1.58% | Yield 2027 * | 1.67% |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| RPRX | Delayed | |
CBOE
| RPRX | Real-time | |
|
Mexican S.E.
| RPRX N | End-of-day quote | |
|
Boerse Muenchen
| RPD | Real-time | |
|
Deutsche Boerse AG
| RPD | Delayed | |
|
Tradegate
| RPD | Real-time | |
|
Börse Stuttgart
| RPD | Delayed | |
|
Xetra
| RPD | Delayed |
Last Transcript : Royalty Pharma plc
| 1 day | +0.13% | ||
| 1 week | +5.11% | ||
| Current month | +4.15% | ||
| 1 month | +10.75% | ||
| 3 months | +14.48% | ||
| 6 months | +40.02% | ||
| Current year | +65.53% |
| 1 week | 60.39 |  | 64.38 |
| 1 month | 56.53 | | 64.38 |
| Current year | 38.29 | | 64.38 |
| 1 year | 34.08 | | 64.38 |
| 3 years | 24.05 | | 64.38 |
| 5 years | 24.05 | | 64.38 |
| 10 years | 24.05 | | 64.38 |
| Manager | Title | Age | Since |
|---|---|---|---|
Pablo Legorreta
CEO | Chief Executive Officer | 62 | 31/12/1995 |
Terrance Coyne
DFI | Director of Finance/CFO | 44 | 31/12/2009 |
Eric Schneider
CTO | Chief Tech/Sci/R&D Officer | - | 20/09/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
Pablo Legorreta
CHM | Chairman | 62 | 31/03/2020 |
Gregory Norden
BRD | Director/Board Member | 68 | 10/02/2020 |
Bonnie Bassler
BRD | Director/Board Member | 63 | 15/06/2020 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 19/08/26 | Don | Executive/Senior Manager | -16,800 | 0.0038% | ||
| 13/08/26 | Sell | Chief Financial Officer | -11,002 | 0.0025% | ||
| 07/08/26 | Don | Chief Financial Officer | -18,500 | 0.0754% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.13% | +5.11% | +77.32% | +116.81% | 28.48B | |
| -0.88% | -2.15% | +58.05% | +105.91% | 1,024B | |
| -1.15% | +2.68% | +54.25% | +71.29% | 663B | |
| -1.44% | +0.38% | +20.65% | +75.54% | 453B | |
| +0.14% | -0.47% | +30.20% | +40.61% | 352B | |
| -1.33% | +4.72% | +24.62% | +47.60% | 304B | |
| -1.15% | +0.30% | -0.69% | +11.83% | 252B | |
| -1.55% | +1.11% | +54.15% | +72.13% | 236B | |
| -0.88% | +1.15% | -14.60% | -54.84% | 206B | |
| -0.15% | +3.65% | +31.24% | +100.90% | 187B | |
| Average | -0.83% | +1.49% | +33.52% | +58.78% | 370.68B | |
| Weighted average by Cap. | -0.95% | +0.58% | +37.94% | +67.38% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 3.5B 3.01B 2.83B 2.59B 4.84B 330B 4.85B 33.45B 12.98B 169B 13.13B 12.84B 546B | 3.81B 3.28B 3.08B 2.82B 5.27B 360B 5.28B 36.45B 14.14B 185B 14.31B 13.99B 595B |
| Net income | 1.47B 1.26B 1.19B 1.09B 2.03B 139B 2.04B 14.06B 5.46B 71.2B 5.52B 5.4B 229B | 1.79B 1.54B 1.45B 1.33B 2.48B 169B 2.49B 17.17B 6.66B 86.92B 6.74B 6.59B 280B |
| Net Debt | 9.11B 7.84B 7.38B 6.74B 12.6B 860B 12.64B 87.16B 33.82B 441B 34.21B 33.46B 1,422B | 9.22B 7.93B 7.46B 6.82B 12.76B 870B 12.79B 88.2B 34.23B 447B 34.62B 33.87B 1,439B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 04/09/26 | US$63.96 | +0.13% | 3,402,567 |
| 03/09/26 | US$63.88 | +1.22% | 2,761,485 |
| 02/09/26 | US$63.11 | +1.27% | 3,143,774 |
| 01/09/26 | US$62.32 | +1.48% | 2,629,306 |
| 31/08/26 | US$61.41 | +0.92% | 3,895,209 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- RPRX Stock
Select your edition
All financial news and data tailored to specific country editions
